Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep-Oct;7(9-10):312-8.
doi: 10.5489/cuaj.1506.

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

Jo-An Seah  1 , Normand Blais, Scott North, Yasmin Rahim, Dean Ruether, Peter C Black, Alexandre R Zlotta, Lori Wood, Srikala S Sridhar
Affiliations

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

Jo-An Seah et al. Can Urol Assoc J. 2013 Sep-Oct.

Abstract

Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Patient flow from initial transurethral resection of bladder tumour to follow-up with a target timelines. TURBT: transurethral resection of the bladder tumour; NC: neoadjuvant chemotherapy; RC: radical cystectomy; PLND: pelvic lymph node dissection. Target timelines: I. TURBT to Pathology Review and Urology Review: 2 weeks. II. Urology to Medical Oncology: 2 weeks. III. Medical Oncology to commencement of NC: As soon as possible, maximum of 2 weeks. IV. Completion of NC to definitive surgical management: within 4–6 weeks.
See this image and copyright information in PMC

References

    1. Canadian Cancer Society. Bladder Cancer Statistics; 2012. http://www.cancer.ca/en/cancer-information/cancer-type/bladder/statistic.... Accessed September 11, 2013.
    1. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174:14–20. doi: 10.1097/01.ju.0000162039.38023.5f. - DOI - PubMed
    1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75. - PubMed
    1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–5. doi: 10.1016/j.eururo.2005.04.006. discussion 205–6. - DOI - PubMed
    1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48:189–99. doi: 10.1016/j.eururo.2005.04.005. discussion 199–201. - DOI - PubMed

LinkOut - more resources